Recent advances in ICB therapy, including those targeting programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) and/or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have allowed strong enhancement of anti-tumor immune responses (Hargadon et al., 2018). Here, CTLA4 is linked to neoplasm.